Results 1 to 10 of about 25,701 (209)

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment

Pharmacogenomics and Personalized Medicine, 2018
Carlos Eduardo Silvado,1 Vera Cristina Terra,1 Carlos Alexandre Twardowschy2 1Comprehensive Epilepsy Program, Hospital de Clinicas, Federal University of Parana (UFPR), Curitiba, Brazil; 2Department of Neurology, Catholic University of Parana (PUCPR ...
Silvado CE, Terra VC, Twardowschy CA
doaj   +1 more source

Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study

Frontiers in Pharmacology, 2017
Existing algorithms account for ~50% of observed variance in warfarin dose requirements after including common polymorphisms. However, they do not perform as well in populations other than Caucasians, in part because some ethno-specific genetic variants ...
Karla Claudio-Campos, Aurora Labastida, Alga Ramos, Andrea Gaedigk, Jessicca Renta-Torres, Dariana Padilla, Giselle Rivera-Miranda, Stuart A. Scott, Stuart A. Scott, Gualberto Ruaño, Carmen L. Cadilla, Jorge Duconge-Soler   +11 more
doaj   +1 more source

Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy

Saudi Pharmaceutical Journal, 2019
The main objective of this study is to assess the effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness in a Jordanian population during the stabilization phase of treatment.
Laith N. AL-Eitan, Ayah Y. Almasri, Rame H. Khasawneh   +2 more
doaj   +1 more source

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population

BMC Medical Genetics, 2009
Background Genetic influences on drug efficacy and tolerability are now widely known. Pharmacogenetics has thus become an expanding field with great potential for improving drug efficacy and reducing toxicity.
Dodoo Alexander NO, Kudzi William, Mills Jeremy J   +2 more
doaj   +1 more source

The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah

Research in Pharmaceutical Sciences, 2018
Polymorphism in the genes encoding CYP2C9 enzyme and VKORC1 reductase significantly influence warfarin dose requirement since patients with CYP2C9*2, CYP2C9*3 and VKORC1 mutant alleles require lower warfarin maintenance doses.
Zohreh Hosseinkhani, Mona Sadeghalvad, Fathemeh Norooznezhad, Reza Khodarahmi, Mohammad Fazilati, Azadeh Mahnam, Ali Fattahi, Kamran Mansouri   +7 more
doaj   +1 more source

Stability of Anticoagulation Following Acenocoumarin in Stroke Patients: Role of Pharmacogenomics and Acquired Factors

Annals of Indian Academy of Neurology
Objective: Pharmacogenomics plays an important role in drug metabolism. A stable anticoagulation is important for primary and secondary prevention of cardioembolic stroke and cerebral venous sinus thrombosis (CVST). We report the role of cytochrome P450 (
Ashish Kant Dubey, Jayantee Kalita, Mohammad Firoz Nizami, Surendra Kumar, Usha Kant Misra   +4 more
doaj   +1 more source

Association between Cytochrome P450 2 C9 and Vitamin K Epoxide Reductase Complex Subunit 1 Polymorphisms with Warfarin dose among Iranian Patients

Research in Molecular Medicine, 2016
Background: Warfarin is a common anticoagulant drug that has a narrow therapeutic index; higher dose causes excessive bleeding and lower dose leads to cerebrovascular clotting and stroke in patients.
Reyhaneh Kameli, Mandana Hasanzad, Zahra Tahmasebi Fard, Mojgan Babanejad, Mahdieh Imeni, Lotfollah Feizi Barnaji, Atoosa Madadkar, Seyed Hamid Jamaldini   +7 more
doaj  

Laying the groundwork: Exploring pesticide exposure and genetic factors in south-eastern Brazilian farmers

Current Research in Toxicology
Brazil is the world leader in pesticide consumption, and its indiscriminate use puts farmers’ health at risk. The CYP2C9 gene encodes the CYP2C9 enzyme, which metabolizes several endogenous substrates and specific xenobiotics, especially pesticides.
Débora Dummer Meira, Victor Nogueira Da Gama Kohls, Matheus Correia Casotti, Luana Santos Louro, Gabriel Mendonça Santana, Thomas Erik Santos Louro, Adriana Madeira Alvares da Silva, Lorena Souza Castro Altoé, Raquel Reis Trabach, Sonia Groisman, Elizeu Fagundes de Carvalho, Jamila Alessandra Perini Machado, Stephanie Seneff, Iúri Drumond Louro   +13 more
doaj   +1 more source

Evaluation of CYP2C8 and CYP2C9 Polymorphisms in Neonates with Patent Ductus Arteriosus Treated with Ibuprofen or Indomethacin: A Retrospective Cohort Study

Journal of Cardiovascular Development and Disease
The pharmacologic management of patent ductus arteriosus (PDA) presents a challenge to clinicians due to the interindividual variability in drug response to available medications.
Shaikha Jabor Alnaimi, Shimaa Aboelbaha, Ibrahim Safra, Mai Abdulla Al Qubaisi, Fouad Abounahia, Ahmed Al Farsi, Liji Cherian, Lizy Philip, Moza Alhail, Gulab Sher, Nader Al-Dewik   +10 more
doaj   +1 more source

GENETIC POLYMORPHISM OF CYTOCHROMES P450 2C9 AND 2C19 IN SLOVENIAN POPULATION

Zdravniški Vestnik, 2003
Background. Cytochrome P450 2C9 (CYP2C9) and 2C19 (CYP2C19) participate in metabolism of many clinically important drugs. Genetic polymorphisms of the CYP2C9 and CYP2C19 genes are described which may affect drug treatment.
Darja Herman, Vita Dolžan, Katja Breskvar   +2 more
doaj